Related Experiment Videos
Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels
Insights
Indomethacin effectively closed the patent ductus arteriosus in premature infants. This study found a higher response rate in infants treated with indomethacin compared to placebo, despite variable drug plasma levels.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Pediatric Cardiology
Background:
- Patent ductus arteriosus (PDA) is a common condition in premature infants.
- PDA can lead to significant complications and mortality.
- Pharmacological closure is a primary treatment strategy.
Purpose of the Study:
- To evaluate the efficacy of indomethacin in closing PDA in premature neonates.
- To compare indomethacin treatment with placebo.
- To assess indomethacin plasma levels and their variability.
Main Methods:
- A randomized, double-blind, placebo-controlled study.
- 23 premature infants were enrolled.
- Infants received either 0.2 mg/kg indomethacin or placebo via gavage.
Main Results:
- 7 out of 12 infants in the indomethacin group responded (closed PDA).
- 2 out of 11 infants in the placebo group responded.
- Indomethacin plasma levels exhibited high variability in peak concentration, time to peak, and half-life.
Conclusions:
- Indomethacin demonstrates effectiveness in closing PDA in premature infants.
- The variability in indomethacin plasma levels warrants further investigation.
- Pharmacological closure remains a viable option for PDA management in neonates.
Abstract:
23 premature infants were placed on a randomized double-blind study to evaluate the effectiveness of indomethacin in closing a patent ductus arteriosus. Infants received 0.2 mg/kg indomethacin or placebo by gavage. In the treatment group, 7 patients responded out of a total of 12, while in the placebo group, 2 responded out of a total of 11. Indomethacin plasma levels were obtained in 6 patients in the treatment group. Plasma levels showed marked variability in peak level (60-3,100 ng/ml), time to peak level (0.5-6 h) and t1/2 (1 to greater than 24 h).